Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity.
In a new approach to the pricing and payer issues beleaguering pharma in general and diabetes drugmakers in particular, Novo Nordisk has teamed up on a project that puts patients with diabetes to work earning discounted copays and other incentives for good behavior.
COPENHAGEN, April 5 (Reuters) - Danish drugmaker Novo
Nordisk has secured the global licence for U.S.
biotech company EpiDestiny's sickle cell disease (SCD) programme
in a bid to offset declining sales in its biopharmaceutical
Competition in the basal insulin market has been fierce, with new competition and payer pressure stymieing growth in the field. But Novo Nordisk just won an FDA approval that could help it stand out in the crowded category.
Just weeks after Novo Nordisk lost out to Sanofi in a race to buy the pipeline-boosting biotech Ablynx, the Danish drugmaker is far from out of the M&A game. For its new board chairman, Novo chose Helge Lund, an oil-industry veteran with plenty of deals under his belt.